<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) June 18, 1997
-------------------------------
NEOTHERAPEUTICS, INC.
- --------------------------------------------------------------------------------
(Exact name of Registrant as specified in charter)
DELAWARE 0-28782 93-0979187
- --------------------------------------------------------------------------------
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
157 TECHNOLOGY DRIVE, IRVINE, CALIFORNIA 92618
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (714) 788-6700
------------------------------
ONE TECHNOLOGY DRIVE, SUITE I-821, IRVINE, CALIFORNIA 92618
- --------------------------------------------------------------------------------
(Former name or former address, if changed, since last report.)
<PAGE> 2
ITEM 5. OTHER EVENTS.
-------------
On June 17, 1997, the shareholders of NeoTherapeutics, Inc., a Colorado
corporation and the predecessor of registrant ("NeoTherapeutics Colorado"),
approved a change of that corporation's state of incorporation from the State of
Colorado to the State of Delaware. The reincorporation was effected by a merger
of NeoTherapeutics Colorado with and into registrant on June 18, 1997.
Registrant, a Delaware corporation, was organized solely for the purpose of
effecting the reincorporation and is the surviving corporation in the merger.
2
<PAGE> 3
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned thereunto duly authorized.
NEOTHERAPEUTICS, INC.
By: /s/ Alvin J. Glasky
---------------------------------
Date: June 18, 1997 Alvin J. Glasky, Ph.D., President
and Chief Executive Officer
3
